Work continues to learn more about causes, treatments and cures for lupus. Lupus Colorado supports the efforts of the Lupus Research Institute.
March 6, 2013
Investigational New Lupus Drug Shown Safe and Effective in Trial Led by Dr. Daniel Wallace, S.L.E. Lupus Foundation Board Member
The new drug in development, epratuzumab, was shown effective and well tolerated in a Phase 2 trial led by world-renowned lupus expert Dr. Daniel Wallace, member of the Board of Directors of our New York organization, the S.L.E. Lupus Foundation.
Results just published in the Annals of the Rheumatic Diseases reported on a randomized placebo-controlled multicenter study of patients with moderate to severe active lupus.
More: Patients with moderate to severe systemic lupus erythematosus experienced improvements in disease activity when assigned to a specific and well-tolerated dose of the CD22-targeted monoclonal antibody epratuzumab in a recent study. Treatment with a specific dose of the CD22-targeted monoclonal antibody epratuzumab improved disease activity and was well tolerated in patients with moderately to severely active SLE. Epratuzumab is currently in Phase 3 trials.
February 22, 2013
Kathleen Sebelius LRI and the S.L.E. Lupus Foundation were among 79 patient groups in the “I Am Essential” coalition delivering a letter to HHS Secretary today urging revisions to a proposed rule from the Centers for Medicare and Medicaid Services (CMS) that would give states the right to determine Medicaid coverage and fees for newly eligible beneficiaries. Our collective concern voiced in the letter is the potential for the proposed guidelines to jeopardize access to patient care.
Jan. 31, 2013
The Lupus Research Institute (LRI) — world’s leading supporter of innovative research in lupus — today awards $3.6 million in Novel Research Grants to allow 12 investigators to pursue ground-breaking studies with potential for transformative results. The $300,000 grants provide scientists with the resources to devote their talent to lupus research for three years. In just its first decade of service, the LRI has awarded more than $40 million for novel research with documented discoveries that are among the most pivotal in lupus.
The Lupus Research Institute (LRI) announced the first $1 million research grants given to lupus investigators by a private research organization. The LRI Distinguished Innovator Initiative was created to address the current lack of treatments in development that could arrest or reverse the disease. The first privately funded awards of this scale in lupus, it challenges the international scientific community to pursue highly promising new ideas on the fundamental causes of lupus that can lead to a cure.
The 12th annual Lupus Research Institute (LRI) Scientific Conference “Forum for Discovery” brought together more than 60 of the country’s top experts in the field to focus their talent on addressing the critical questions in the autoimmune disease lupus. LRI-funded investigators presented new findings on a broad range of topics including genetic factors that predispose certain individuals to lupus, how the lupus immune system turns against the body, and novel approaches to treat the disease.